Important Safety Information

Indication and clinical use:

AREXVY is a vaccine indicated for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults 60 years of age and older.

Pediatrics: Safety and efficacy not assessed.

Geriatrics: Clinical studies include participants ≥65 years of age, and their data contributes to the overall assessment of safety and efficacy of AREXVY.

Relevant warnings and precautions:

  • There is no data for the use of AREXVY in pregnant individuals. Not recommended during pregnancy or in breast-feeding/lactating individuals
  • Postpone vaccination in individuals suffering from an acute severe febrile illness
  • Syncope
  • Caution driving and operating machinery
  • Caution in individuals with thrombocytopenia or any coagulation disorder
  • Protective immune response may not be elicited in all vaccinees
  • Systemic immunosuppressive medications and immunodeficiency

For more information:

Please consult the Product Monograph at gsk.ca/AREXVY/PM for important information relating to warnings, precautions, adverse reactions, drug interactions, and dosing. To request a Product Monograph or to report an adverse event, please call 1-800-387-7374.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

104605 | 07/24

Open cookie banner
Hide cookie banner